Ionis Pharmaceuticals, Inc. was incorporated in California in 1989 and changed its state of incorporation to Delaware in January 1991. The company has spent three decades developing RNA-targeted drugs and has grown into a fully integrated commercial-stage biotechnology company with seven listed drugs and a strong pipeline across neurology, cardiometabolic diseases and other high-demand areas for patients. It continues to advance next-generation RNA targeting technologies through independent and collaborative development to deliver innovative therapies to patients with serious diseases. 

Expected P&L on Expiry

Key Stats

Pricing Model

About IONS20260417C75